| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/MYC.12236 |
| P698 | PubMed publication ID | 25175306 |
| P50 | author | Emmanuel Roilides | Q61097982 |
| P2093 | author name string | Maria Simitsopoulou | |
| Charalampos Antachopoulos | |||
| P2860 | cites work | Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008) | Q58814209 |
| Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication | Q21563342 | ||
| Novel perspectives on mucormycosis: pathophysiology, presentation, and management | Q24530554 | ||
| Recent advances in the management of mucormycosis: from bench to bedside | Q24642450 | ||
| Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species | Q28389719 | ||
| Hsp90 orchestrates stress response signaling governing fungal drug resistance | Q28475988 | ||
| Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis | Q30482669 | ||
| Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis | Q33805542 | ||
| Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice | Q33806127 | ||
| Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice | Q33826450 | ||
| Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies | Q33898647 | ||
| Newer systemic antifungal agents : pharmacokinetics, safety and efficacy | Q33981062 | ||
| In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. | Q34110440 | ||
| Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. | Q34120234 | ||
| Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole | Q34301592 | ||
| Epidemiology and outcome of zygomycosis: a review of 929 reported cases | Q34440240 | ||
| In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts | Q34680661 | ||
| Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus | Q35647730 | ||
| Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. | Q35848794 | ||
| The iron chelator deferasirox protects mice from mucormycosis through iron starvation | Q35960985 | ||
| Combination therapy for mucormycosis: why, what, and how? | Q35974333 | ||
| The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial | Q36058200 | ||
| Statins in the critically ill | Q36369699 | ||
| Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage | Q36425055 | ||
| In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. | Q36558376 | ||
| Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis | Q36584655 | ||
| Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro | Q36744800 | ||
| Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). | Q36862446 | ||
| Emerging fungal infections in solid organ transplant recipients | Q36949523 | ||
| Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. | Q36983268 | ||
| Dynamic duo takes down fungal villains | Q37117696 | ||
| In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | Q37274705 | ||
| Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients | Q37385419 | ||
| Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis | Q37475959 | ||
| Changing epidemiology of an emerging infection: zygomycosis. | Q37597529 | ||
| Incidence of zygomycosis in transplant recipients | Q37597541 | ||
| Outbreaks of zygomycosis in hospitals | Q37597551 | ||
| New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance | Q37608276 | ||
| Pathogenesis of mucormycosis | Q37976046 | ||
| Epidemiology and clinical manifestations of mucormycosis | Q37976047 | ||
| Host defenses against zygomycetes | Q37976050 | ||
| Why is mucormycosis more difficult to cure than more common mycoses? | Q38166447 | ||
| Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity | Q39510313 | ||
| In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model | Q39652289 | ||
| Isavuconazole therapy protects immunosuppressed mice from mucormycosis | Q39684037 | ||
| Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. | Q39739431 | ||
| Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor | Q41440833 | ||
| Role of hemopoietic growth factors and cytokines in host defense against fungal infections | Q41708394 | ||
| Successful medical management of isolated renal zygomycosis: case report and review | Q41730974 | ||
| Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice | Q42095363 | ||
| In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents | Q42139858 | ||
| In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. | Q42151635 | ||
| ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. | Q42230463 | ||
| Synergistic effect of posaconazole and caspofungin against clinical zygomycetes | Q42627361 | ||
| Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins | Q42706346 | ||
| Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes | Q42931968 | ||
| Comparison of lipid amphotericin B preparations in treating murine zygomycosis | Q43111731 | ||
| In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes | Q43174715 | ||
| Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. | Q43184603 | ||
| Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. | Q43189988 | ||
| Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor | Q43613091 | ||
| In vitro susceptibilities of zygomycetes to conventional and new antifungals | Q44257265 | ||
| Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes | Q44295421 | ||
| Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). | Q44468410 | ||
| Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. | Q44738457 | ||
| In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi | Q46186763 | ||
| Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis | Q46495013 | ||
| Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae | Q46577790 | ||
| Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes | Q46768531 | ||
| Antifungal activity of statins against Aspergillus species. | Q46886084 | ||
| Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation | Q47860890 | ||
| Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. | Q51172068 | ||
| How does antifungal pharmacology differ for mucormycosis versus aspergillosis? | Q51173325 | ||
| Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. | Q53889247 | ||
| Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007 | Q58405315 | ||
| P304 | page(s) | 40-47 | |
| P577 | publication date | 2014-08-31 | |
| P1433 | published in | Mycoses | Q1956531 |
| P1476 | title | Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs | |
| P478 | volume | 57 Suppl 3 |
| Q54256022 | Challenges in the diagnosis and treatment of mucormycosis. |
| Q60916367 | Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis |
| Q40088527 | Immune responses to Mucorales growth forms: Do we know everything? |
Search more.